Breast cancer is the most common cancer in women and a multidisciplinary approach has reduced breast cancer mortality. Early stage and locally advanced breast cancers require systemic therapy to reduce recurrence and relapse. Pathologic complete response (pCR) has been one of the main targets of neoadjuvant systemic therapy. With the advent of immune checkpoint inhibitors (ICIs), Immunotherapy has revolutionized the treatment of solid tumors. Immunotherapy in breast cancer has been used especially in the immunogenic subtype of TNBC (triple-negative breast cancer), which has higher levels of TIL (tumor-infiltrating lymphocytes). The KEYNOTE-522 study showed that adding pembrolizumab to neoadjuvant chemotherapy increased pCR rates in patients with early-stage TNBC. The IMPASSION031 study also showed that the combination of atezolizumab and nab-paclitaxel increased the pCR rate from 41% to 58%. In the KEYNOTE-355 study, the addition of pembrolizumab to chemotherapy in patients with TNBC with a combined positive score (CPS) ≥10 significantly improved progression-free and overall survival. Current studies are investigating various combinations of chemotherapy and immunotherapy, as well as new immunotherapeutic agents in combination with tumor vaccines, oncolytic viruses and adaptive cellular therapy.